Search

Your search keyword '"Unger, C."' showing total 1,031 results
Start Over Author "Unger, C."
1,031 results on '"Unger, C."'

203. Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells

Author

Unger, C., primary, Gao, S., additional, Cohen, M., additional, Jaconi, M., additional, Bergstrom, R., additional, Holm, F., additional, Galan, A., additional, Sanchez, E., additional, Irion, O., additional, Dubuisson, J. B., additional, Giry-Laterriere, M., additional, Salmon, P., additional, Simon, C., additional, Hovatta, O., additional, and Feki, A., additional

Published
2009
Full Text
View/download PDF

223. A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging

Author

Bornmann, C., primary, Graeser, R., additional, Esser, N., additional, Ziroli, V., additional, Jantscheff, P., additional, Keck, T., additional, Unger, C., additional, Hopt, U. T., additional, Adam, U., additional, Schaechtele, C., additional, Massing, U., additional, and von Dobschuetz, E., additional

Published
2007
Full Text
View/download PDF

230. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)

Author

UCL - (SLuc) Unité d'oncologie médicale, Van Cutsem, E., Cunningham, D., Huinink, WWT., Punt, CJA, Alexopoulos, C.G., Dirix, L., Symann, Michel, Blijham, GH, Cholet, P, Fillet, G., Van Groeningen, C, Vannetzel, JM, Levi, F, Panagos, G, Unger, C., Wils, J., Cote, C, Blanc, C, Herait, P, Bleiberg, H., UCL - (SLuc) Unité d'oncologie médicale, Van Cutsem, E., Cunningham, D., Huinink, WWT., Punt, CJA, Alexopoulos, C.G., Dirix, L., Symann, Michel, Blijham, GH, Cholet, P, Fillet, G., Van Groeningen, C, Vannetzel, JM, Levi, F, Panagos, G, Unger, C., Wils, J., Cote, C, Blanc, C, Herait, P, and Bleiberg, H.

Abstract

The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC). 107 patients with documented progression of metastatic CRC during 5-FU were treated with CPT-11 350 mg/m(2) once every 3 weeks in a multicentre phase II study. Tumour response and toxicity were assessed using WHO criteria. Changes in performance status (PS), weight and pain were also measured. The WHO response rate was 13/95 (13.7%, 95% CI 7.5% to 22.3%) eligible patients with a median duration of response of 8.5 months (37 weeks, range: 18-53 +). There was also a high rate of disease stabilisation (44.2%) with a median duration of 4.8 months. The probability of being free of progression at 4 months was 50%. Median survival from first administration of CPT-11 was 10.4 months or 45 weeks (range: 3-66 + weeks). There was weight stabilisatian or gain in 81% (73/90) of patients, a favourable outcome in PS in 91% (82/90) (improvement of WHO PS 2 or stabilisation of PS 0-1), and pain relief in 54% (26/48). There were no toxic deaths. Neutropenia was short-lasting and non-cumulative. Diarrhoea grade greater than or equal to 3 occurred in 7% of cycles and 28/107 (26%) of patients. CPT-11 350 mg/m(2) once every 3 weeks has an encouraging degree of activity in progressive metastatic CRC truly resistant to 5-FU with a relatively high rate of tumour growth control translated into clinical benefit. The toxicity profile of CPT-11 is becoming better understood and has been considerably improved. (C) 1999 Elsevier Science Ltd. All rights reserved.

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results